270 related articles for article (PubMed ID: 23593455)
1. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
[TBL] [Abstract][Full Text] [Related]
2. Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
Li Y; Xie J; Wang H; Han Y; Wang N; Thio CL; Li T
Antivir Ther; 2017; 22(6):523-527. PubMed ID: 28195558
[TBL] [Abstract][Full Text] [Related]
3. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
[TBL] [Abstract][Full Text] [Related]
5. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
[TBL] [Abstract][Full Text] [Related]
6. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
7. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
8. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
[TBL] [Abstract][Full Text] [Related]
9. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
10. CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy.
Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M
Antivir Ther; 2014; 19(4):429-33. PubMed ID: 24430489
[TBL] [Abstract][Full Text] [Related]
11. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K
J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890
[TBL] [Abstract][Full Text] [Related]
12. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Maylin S; Boyd A; Delaugerre C; Zoulim F; Lavocat F; Simon F; Girard PM; Lacombe K
Clin Vaccine Immunol; 2012 Feb; 19(2):242-8. PubMed ID: 22190396
[TBL] [Abstract][Full Text] [Related]
13. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
14. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
[TBL] [Abstract][Full Text] [Related]
15. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
Idoko J; Meloni S; Muazu M; Nimzing L; Badung B; Hawkins C; Sankalé JL; Ekong E; Murphy R; Kanki P; Thio CL
Clin Infect Dis; 2009 Oct; 49(8):1268-73. PubMed ID: 19772386
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hepatitis B markers in Senegalese HIV-1-infected patients.
Lô G; Sow-Sall A; Diop-Ndiaye H; Mandiouba NC; Thiam M; Diop F; Ndiaye O; Gueye SB; Seck SM; Dioura AA; Mbow M; Gaye-Diallo A; Mboup S; Touré-Kâne C
J Med Virol; 2016 Mar; 88(3):461-5. PubMed ID: 26252424
[TBL] [Abstract][Full Text] [Related]
17. [Atypical serological profiles in hepatitis B infections: investigation of S gene mutations in cases with concurrently positive for HBsAg and anti-HBs].
Aydın N; Kırdar S; Uzun N; Eyigör M; Sayan M
Mikrobiyol Bul; 2016 Oct; 50(4):535-543. PubMed ID: 28124958
[TBL] [Abstract][Full Text] [Related]
18. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.
Crane M; Sirivichayakul S; Chang JJ; Avihingsanon A; Ubolyam S; Buranapraditkun S; Thantiworasit P; Wightman F; Locarnini S; Matthews G; Dore GJ; Ruxrungtham K; Lewin SR
J Virol; 2010 Mar; 84(6):2657-65. PubMed ID: 20053751
[TBL] [Abstract][Full Text] [Related]
19. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
20. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
